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Cutaneous adverse drug reactions (CADRs) are a common 
complication of antiretroviral therapy (ART) and of drugs 
used to treat opportunistic infections.1 The common clinical 
manifestations range from mild maculopapular eruptions 
to the more severe recognised spectrum of Stevens-Johnson 
Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug 
reaction with eosinophilia and systemic symptoms (DRESS). 
Occasionally, however, a rare manifestation of CADR occurs 
which presents a diagnostic dilemma.
Case report
A 24-year-old South African woman was newly diagnosed with 
disseminated culture-positive tuberculosis (TB) and HIV. Her 
CD4 count was 77 cells/mm3 and she had no prior TB history 
(including contacts). The patient was initiated on Rifafour, 
and cotrimoxazole prophylaxis was started 9 days later. 
After a further 2 weeks, ART was initiated (tenofovir (TDF), 
lamivudine and efavirenz). 
One month after ART initiation, the patient presented with 
sudden-onset generalised, pustular, itchy rash, associated with 
1 week of fatigue, nausea, vomiting and painful feet. She had 
renal impairment (creatinine 521 µmol/l) and was anaemic 
(haemoglobin 6.1g/dl). Treatment with TDF, cotrimoxazole 
and rifampicin was ceased, and the patient was referred for 
further assessment. 
On examination, she was tachycardic but apyrexial. She had 
a widespread pustular rash sparing the palms and soles (Fig. 
1). Pustules were <5 mm in size and monomorphic on an 
erythematous background, with areas of desquamation on the 
lower limbs. She had no mucous membrane involvement, but 
had manifested angular cheilitis and oral candidiasis. Tender 
hepatomegaly and painful, peripheral sensory neuropathy 
were noted. 
A pus swab from one of the lesions showed neutrophils, but 
Gram-stain and culture testing were both negative. Testing of a 
pustule aspirate for varicella zoster virus by polymerase chain 
reaction (PCR) was also negative. Blood, urine and sputum 
bacterial cultures were negative, as was syphilis serology, serum 
cryptococcal latex antigen test and hepatitis B serology. In 
addition to anaemia, the patient had a leucocytosis of 11.5 x 
109/l (93% neutrophils), but her platelet count was normal. She 
was hypo-albuminaemic (19 g/l) with mild liver dysfunction 
(total bilirubin 23 µmol/l, alkaline phosphatase 171 U/l, 
gamma-glutamyl transferase 111 U/l, alanine transaminase 
34 U/l and aspartate transaminase 58 U/l). A chest X-ray 
showed diffuse bi-basal nodularity. Necrotic lymph nodes and 
multiple splenic hypodensities, suggestive of abdominal TB, 
were evident on abdominal ultrasound. 
Two days after admission, treatment with abacavir was 
started to replace TDF, and the patient was started on 
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acyclovir, pending the results of investigations. 
Rifampicin was re-introduced on day 4. Her 
rash had considerably improved after 8 days 
and her creatinine level diminished to 303 
µmol/l. Renal biopsy was delayed due to the 
overlying skin lesions. 
Histopathology of a skin biopsy on admission 
showed basket-weave hyperkeratosis, spongiosis 
and an intracorneal pustule, containing 
neutrophils and occasional lymphocytes (Fig. 
2). Small cocci were noted within the pustule 
and a mild superficial perivascular lymphocytic 
infiltrate was present. Superficial dermal vessels 
were mildly dilated and contained marginated 
neutrophils. Special stains for fungi and acid-
fast bacilli were negative and no granulomas, 
dysplastic or malignant cells were found. A 
histopathological diagnosis of acute generalised 
exanthematous pustulosis (AGEP) was made. 
Multi-drug resistant TB (MDR-TB) was 
subsequently diagnosed on the basis of a urine 
culture (sampled on admission) and her TB 
regimen was altered. She was discharged with 
a clinical diagnosis of acute kidney injury 
secondary to TDF, disseminated MDR-TB, and 
AGEP most likely secondary to cotrimoxazole 
or TDF. She has had a good clinical response 
and, at the time of writing, remains in care 7 
months post discharge.
Discussion
AGEP is an uncommon severe cutaneous 
reaction associated with drug exposure in 
90% of cases. The remaining 10% of cases 
have been attributed to viral infections, 
vaccines, spider bites, heavy metal exposure, 
chemotherapy and radiation.2 The reaction has 
a mortality rate of 2%, typically occurring in 
the elderly with co-morbidities, and is related 
to septic complications.2 A wide spectrum of 
pustular skin diseases forms the differential 
diagnosis, including pustular psoriasis, 
Sweet’s syndrome (acute febrile neutrophilic 
dermatosis), pustular erythema multiforme, 
TEN, DRESS and bullous impetigo.2,3 In 
our patient, disseminated varicella was also 
considered. The combination of clinical and 
histological features together with appropriate 
drug exposure is usually enough to make the 
diagnosis of AGEP.2,3
To date, a single case of AGEP has been 
described in an HIV-infected patient with 
a CD4 count of 220 cells/mm3, attributed 
to boosted darunavir, which recurred on 
atazanavir re-challenge.5 Protease inhibitors 
(indinavir and boosted lopinavir) have also 
been implicated in AGEP in patients receiving 
post-exposure prophylaxis.6,7 Nucleoside/
nucleotide reverse transcriptase inhibitors 
have not been implicated as causal agents. 
However, there are case reports of AGEP 
following cotrimoxazole treatment in HIV-
negative patients.8,9
The pathophysiology of AGEP involves 
drug-specific T cell activation by dendritic cells 
followed by T cell expansion and migration 
to the dermis and epidermis. The T cells are 
activated to produce high levels of neutrophil-
attracting chemokine (CXCL8) and express 
a type 1 T-helper (Th-1) cytokine profile 
(granulocyte-macrophage colony-stimulating 
factor, interferon gamma and tumour necrosis 
factor-alpha). Stimulated keratinocytes recruit T 
cells and neutrophils to the inflamed skin. Drug-
specific cytotoxic CD8 T cells are responsible for 
killing keratinocytes and for vesicle formation, 
while neutrophils migrate along the CXCL8 
gradient into the vesicles to form pustules.2 In 
the case described here, the delayed presentation 
following initiation of cotrimoxazole, the most 
likely causative agent, may have been attributed 
to reduced drug-specific T cell activation in 
advanced HIV disease. 
Characteristic features of AGEP include 
an acute generalised cutaneous eruption of 
whitish non-follicular, sterile pustules <5 mm 
in size and on a background of erythema, 
which may be accompanied by a burning 
sensation. Lesions often start on the face or 
intertrigenous areas, moving to the trunk and 
limbs within a few hours. The reaction rarely 
affects the palms and soles and has mucous 
membrane involvement in only 20% of cases. 
Half of affected patients may report other skin 
symptoms. The rash lasts for a mean of 9.4 
days (range 4 - 10), followed by desquamation. 
The rash is accompanied by a fever >38°C that 
lasts for approximately 1 week.3 The onset 
of rash follows 2 distinct patterns: (i) a rapid 
onset after drug ingestion (a few hours to 2 
- 3 days) which is most commonly associated 
with antibiotics and may signify previous 
sensitisation; and (ii) an onset after 1 - 3 
weeks (mean 11 days), which may result from 
primary sensitisation.3,4
A neutrophilia occurs in 90% of cases, 
while up to 30% have mild eosinophilia. Renal 
dysfunction (predominantly pre-renal) occurs 
in one-third of cases. Rarely, hypocalcaemia 
and a mild elevation in amino-transferases 
have been observed.2,3 The skin biopsy is 
characterised by spongiform subcorneal or 
intradermal pustules, papillary oedema and 
neutrophilic perivascular infiltrates.2,3
When there is doubt over the causal agent, 
and there are no alternative therapeutic agents, 
Fig. 2. (a) Intracorneal pustule (x20) containing (b) 
neutrophils and occasional lymphocytes (x200).
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confirmatory tests may be performed under 
specialist supervision: 
• Drug provocation testing: although the gold 
standard for CADR, this is contra-indicated 
in AGEP.10
• Patch testing: although this has only a 50% 
sensitivity and 85% specificity, it is the best 
available test for practical reasons.2
• The lymphocyte transformation test (LTT): 
requires a specialised laboratory, but has an 
improved sensitivity of 78% with varying 
specificity.2
Treatment of AGEP is symptomatic, with 
withdrawal of treatment with the offending 
drug. Antibiotics are not indicated unless 
secondary infection occurs. Corticosteroid 
treatment has been used, but is not required 
in the majority of cases.3
Conclusion
This case highlights a rare adverse drug reaction 
that can occur in HIV-infected patients and is 
an important differential diagnosis of a pustular 
eruption. Antibiotics are the most common 
causative agents, and protease inhibitors are the 
most commonly implicated ART drugs. Early 
recognition and drug withdrawal are vital. If 
drug re-challenge is required, this should be 
done under specialist supervision.
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